Omeros Corporation
CHIMERIC INHIBITOR MOLECULES OF COMPLEMENT ACTIVATION

Last updated:

Abstract:

The present invention relates to novel chimeric molecules of ficolin-associated polypeptides, such as fusion polypeptides for the use in the treatment of conditions associated with inflammation, apoptosis, autoimmunity, coagulation, thrombotic or coagulopathic related diseases. The present invention further relates to nucleic acid molecules encoding such fusion polypeptides, vectors and host cells used in the production of the fusion polypeptides.

Status:
Application
Type:

Utility

Filling date:

16 Jul 2020

Issue date:

14 Jan 2021